| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $4.4M | — | +4.1% |
| SG&A Expense | $2.4M | — | +3.7% |
| Operating Income | -$6.8M | — | -4.0% |
| Net Income | -$6.8M | — | -7.6% |
| EPS (Basic) | -$0.08 | — | +27.3% |
| EPS (Diluted) | -$0.08 | — | +27.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $19.7M | +21.7% | +51.8% |
| Accounts Receivable | $12K | — | — |
| Current Assets | $21.5M | +20.4% | +45.1% |
| Total Assets | $42.4M | +7.5% | +19.5% |
| Current Liabilities | $6.8M | +2.6% | +9.3% |
| Total Liabilities | $23.3M | -1.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$6.2M | — | -20.0% |
| Capital Expenditures | $3K | — | -40.0% |
| Investing Cash Flow | -$3K | — | +40.0% |
| Financing Cash Flow | $9.7M | — | +5814.1% |
| Free Cash Flow | -$6.2M | — | -19.9% |
| -2.4% |
| Stockholders' Equity | $19.1M | +21.3% | +64.2% |